In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates
Our results showed that all combinations including relebactam led to higher "non-resistance" rates against AmpC-overproducing P. aeruginosa clinical isolates. The best activity was achieved by combining ceftolozane and relebactam, that might therefore be considered as an excellent clinical alternative against AmpC overproducers.
Authors
- Christophe Le Terrier (ORCID: https://orcid.org/0000-0002-5455-5576)
- Alaaeldin Mohamed Saad (ORCID: https://orcid.org/0000-0002-6072-1681)
- Patrice Nordmann (ORCID: https://orcid.org/0000-0002-1343-1622)
- Otávio Hallal Ferreira Raro (ORCID: https://orcid.org/0000-0001-7374-0788)
- Laurent Poirel (ORCID: https://orcid.org/0000-0001-5160-5286)
Institutions
- University of Fribourg (CH)
- Zagazig University (EG)
- University Hospital of Geneva (CH)
Publication Details
- Journal
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1007/s10096-024-04965-x
- Citations
- 9
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.53
Funders
- Université de Fribourg